Table 1.
Period | Screening and baseline | Treatment (w1–4) | Follow-up (w5–12) | Follow-up (w13–24) | |||
---|---|---|---|---|---|---|---|
Week (W) | W −1 | W1 | W2 | W3 | W4 | W12 | W24 |
Eligibility | × | ||||||
CT or MRI | × | ||||||
General information | × | ||||||
Physical examination | × | × | × | × | |||
Medical history and demography | × | ||||||
Informed consent | × | ||||||
WAB | × | × | × | × | |||
BDAE | × | × | × | × | |||
Disease Prognosis Scale of ischaemic stroke | × | × | × | × | |||
MRI (3D-T1, RS-fMRI, Task-fMRI, DTI) | × | × | × | × | |||
EEG | × | × | × | × | |||
ERP | × | × | × | × | |||
Discomfort and acceptance of acupuncture | × | × | × | × | × | × | |
Assessment of blind method | × | ||||||
Adverse event | × | × | × | × | × | ||
Compliance | × | × | × | × | × |
CT, computed tomography; MRI, magnetic resonance imaging; WAB, Western Aphasia Battery; BDAE: Boston Diagnostic Aphasia Examination; RS-fMRI, resting-state functional magnetic resonance imaging; DTI, diffusion tensor imaging; EEG, electroencephalogram; ERP, event-related potentials.